P
Peter Eu
Researcher at Peter MacCallum Cancer Centre
Publications - 49
Citations - 2604
Peter Eu is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Prostate cancer & PET-CT. The author has an hindex of 19, co-authored 44 publications receiving 1910 citations. Previous affiliations of Peter Eu include University of Melbourne.
Papers
More filters
Journal ArticleDOI
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman,Michael S Hofman,John Violet,Rodney J. Hicks,Rodney J. Hicks,Justin Ferdinandus,Sue Ping Thang,Tim Akhurst,Tim Akhurst,Amir Iravani,Grace Kong,Aravind S. Ravi Kumar,Declan G. Murphy,Declan G. Murphy,Peter Eu,Price Jackson,Mark Scalzo,Scott Williams,Shahneen Sandhu,Shahneen Sandhu +19 more
TL;DR: The findings show that radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 has high response rates, low toxic effects, and reduction of pain in men with metastatic castration-resistant prostate cancer who have progressed after conventional treatments.
Journal ArticleDOI
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
John Violet,Price Jackson,Justin Ferdinandus,Shahneen Sandhu,Tim Akhurst,Amir Iravani,Grace Kong,Aravind S. Ravi Kumar,Sue Ping Thang,Peter Eu,Mark Scalzo,Declan G. Murphy,Declan G. Murphy,Scott Williams,Scott Williams,Rodney J. Hicks,Rodney J. Hicks,Michael S Hofman,Michael S Hofman +18 more
TL;DR: 177Lu-PSMA-617 delivers high absorbed doses to tumor, with a significant correlation between whole-body tumor dose and PSA response, providing a rationale for patient-specific dosing.
Journal ArticleDOI
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
Michael S Hofman,Grace Kong,Oliver C. Neels,Peter Eu,Emily Hong,Rodney J. Hicks,Rodney J. Hicks +6 more
TL;DR: Assessment of the management impact of incremental diagnostic information obtained from this technique compared with conventional staging for neuroendocrine tumours and other somatostatin‐receptor expressing tumours.
Journal ArticleDOI
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet,Shahneen Sandhu,Amir Iravani,Justin Ferdinandus,Sue-Ping Thang,Grace Kong,Aravind S. Ravi Kumar,Tim Akhurst,David A. Pattison,Alexis Beaulieu,Jennifer Mooi,Ben Tran,Christina Guo,Victor Kalff,Declan G. Murphy,Price Jackson,Peter Eu,Mark Scalzo,Scott Williams,Rodney J. Hicks,Michael S Hofman +20 more
TL;DR: This expanded 50-patient cohort of men with extensive prior therapy confirms an earlier report of high response rates, low toxicity, and improved quality of life with 177Lu-PSMA radioligand therapy.
Journal ArticleDOI
Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.
Louise Emmett,Louise Emmett,Megan Crumbaker,Bao Ho,Kathy Willowson,Peter Eu,Lalith Ratnayake,Richard J. Epstein,Ashley Blanksby,Lisa G. Horvath,Alexander Guminski,Kate L. Mahon,Craig Gedye,Charlotte Yin,Phillip D. Stricker,Anthony M. Joshua +15 more
TL;DR: PSMA PET plays an important role in predicting treatment response to Lu‐PSMA and in identifying subsequent patterns of failure, which may aid in determining the next best treatment options, according to a phase 2 prospective pilot trial.